drugset

drugset / Trial / NCT00367835

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

NCT00367835 ↗

Phase 3 Completed 217 enrolled Shire

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess efficacy and safety of SPD503(guanfacine hydrochloride) in subjects with ADHD and oppositional symptoms.

Timeline

Start: 2006-12-04
Primary completion: 2008-01-04
Completion: 2008-01-04

Publications

Results Connor DF, Findling RL, Kollins SH, Sallee F, Lopez FA, Lyne A, Tremblay G. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010 Sep;24(9):755-68. doi: 10.2165/11537790-000000000-00000.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guanfacine	Small molecule	1 mg	—
Subject	Guanfacine	Small molecule	2 mg	—
Subject	Guanfacine	Small molecule	3 mg	—
Subject	Guanfacine	Small molecule	4 mg	—

Indications